{
    "nct_id": "NCT02359552",
    "title": "A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2020-10-21",
    "description_brief": "This is a Phase II, randomized, double blind, placebo controlled, parallel group, proof of concept three-site study, to evaluate the effect of Rasagiline in the regional brain metabolism on 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG-PET).",
    "description_detailed": "The study consists of two phases: a 24 week double blind placebo controlled treatment period and a 4 week follow up period. Patients will be randomized in a 1: 1 ratio at baseline to receive either Rasagiline or matching placebo\n\nThe study drug will be given as 0.5 mg dose once daily for the 4 weeks, then increases to 1 mg daily for the next 20 weeks. A total of 50 subjects will be enrolled: 25 will receive Rasagiline and 25 will receive matching placebo for the 24-week treatment period.\n\nPrimary objective is to determine if exposure to 1 mg of Rasagiline daily is associated with improved regional brain metabolism in the treatment group compared to the placebo group in Alzheimer's Disease patients",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "Of 96 screened participants, 50 met inclusion criteria and were enrolled and randomized to treatment.",
            "recruitmentDetails": "Patients were recruited based on physician referral from three Cleveland Clinic sites between May 2015 and January 2018",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Placebo",
                    "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nPlacebo"
                },
                {
                    "id": "FG001",
                    "title": "Rasagiline",
                    "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nRasagiline"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "25"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "25"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "22"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "21"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "4"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "4"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Placebo",
                    "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nPlacebo"
                },
                {
                    "id": "BG001",
                    "title": "Rasagiline",
                    "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nRasagiline"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "25"
                        },
                        {
                            "groupId": "BG001",
                            "value": "25"
                        },
                        {
                            "groupId": "BG002",
                            "value": "50"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "73.44",
                                            "spread": "7.12"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "74.72",
                                            "spread": "7.35"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "74.08",
                                            "spread": "7.19"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "11"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "14"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "25"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "14"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "11"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "25"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Ethnicity (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Hispanic or Latino",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Not Hispanic or Latino",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "25"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "25"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "50"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "24"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "24"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "48"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "25"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "25"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "50"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Alzheimer's Disease Assessment Scale - Cognitive 11 score",
                    "description": "The ADAS-Cog 11 is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates worse impairment. Scores range test from 0 (best) to 70 (worse). We used total ADAS-Cog 11 scores, which is a sum of individual subscales.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "27.96",
                                            "spread": "10.53"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "23.2",
                                            "spread": "6"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "25.58",
                                            "spread": "8.81"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Mini Mental Status Examination (MMSE)",
                    "description": "The MMSE is a brief, frequently used screening instrument for AD drug studies. The MMSE evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons. A lower score indicates more cognitive impairment. The highest score is 30.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "19.04",
                                            "spread": "4.61"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "21.24",
                                            "spread": "3.54"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "20.14",
                                            "spread": "4.21"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) score",
                    "description": "The ADCS-ADL is an activities-of-daily-living inventory developed by the ADCS to assess functional performance in participants with AD. Using a structured interview format, study partners are queried as to whether participants attempted each item in the inventory during the past 4 weeks and their level of performance. The ADCS-ADL provides a total score from 0-78, with a lower score indicating greater severity.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "58.2",
                                            "spread": "11.1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "61.88",
                                            "spread": "8.44"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "60",
                                            "spread": "9.96"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Neuropsychiatric Inventory (NPI) score",
                    "description": "The behavioral outcome measure for this trial is the Neuropsychiatric Inventory (NPI). The NPI evaluates both the frequency and severity of 10 neuropsychiatric disturbances. Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1=mild, 2=moderate, 3=severe). The overall score is calculated by summing the severity and frequency of the subscale measures. The range of scores is from 0-40. A score of 0 indicates no neuropsychiatric disturbance while a score of 40 indicates severe disturbance.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "8.28",
                                            "spread": "8.97"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "7.62",
                                            "spread": "7.61"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "7.96",
                                            "spread": "8.25"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "digit span",
                    "description": "The Digit Span consists of repetition of increasing long strings of digits presented at 1 per second as read by the examiner and repeated by the subject.The score is the maximum number of digits the patient can repeat until they fail twice in a row. The reverse digit span is identical to the forward digit span except that the patient repeats the presented digits in reverse order. The score is the maximum number of digits the patient can repeat in reverse order until they fail twice in a row. Each correct response is worth one point with a maximum total score of 28. A higher score is better.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "11.76",
                                            "spread": "3.23"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "13.08",
                                            "spread": "2.75"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "12.42",
                                            "spread": "3.04"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Controlled Oral Word Association Test (cowat) score",
                    "description": "Study participants are instructed, \"I want to see how many words you can say beginning with a certain letter in one minute.\" The study participant's responses are recorded on the worksheet. Study participants are then given an additional one minute for each of two different letters using similar instructions. The score is the total number of acceptable words for the three trials combined. A higher score represents better performance. The range of scores is from 0-100.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "21.16",
                                            "spread": "13.16"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "26.72",
                                            "spread": "12.6"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "23.94",
                                            "spread": "13.06"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Quality of Life - Alzheimer's Disease (QoL-AD)",
                    "description": "The Quality of Life in Alzheimer's Disease (QoL-AD) is a commonly used 13 item quality of life (QoL) scale that assesses items specific to QoL in patients with cognitive impairment. It is administered to the research partner who answers for the patient. Points are assigned to each item as follows: poor = 1, fair = 2, good = 3, excellent = 4.The total score is the sum of all 13 items. The range of score is 0 to 52. A score of 0 indicates severe impairment and a score of 52 indicating no impairment.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "39.58",
                                            "spread": "5.24"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "36.73",
                                            "spread": "5.35"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "38.22",
                                            "spread": "5.43"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Change in Regional Glucose Metabolism Between Week 24 and Baseline as Measured by 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET).",
                    "description": "The primary outcome measure is the change from baseline to week 24 in FDG-PET as measured by Standard Uptake Units Regional (SUVR) in several pre-specified brain regions including the medial temporal, lateral temporal, posterior cingulate - precuneus, inferior parietal, middle frontal, anterior cingulate, and striatum. The SUVR change was calculated by subtracting the value at 24 weeks from baseline values. Negative values indicate increased hypometabolism (i.e. worsening of cell function).",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "SUVR",
                    "timeFrame": "24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nPlacebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Rasagiline",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nRasagiline"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "25"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Middle Frontal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.032",
                                            "spread": "0.030"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.011",
                                            "spread": "0.030"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Anterior Cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.020",
                                            "spread": "0.021"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.003",
                                            "spread": "0.026"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Superior Frontal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.016",
                                            "spread": "0.022"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.003",
                                            "spread": "0.018"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Striatum",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.024",
                                            "spread": "0.029"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.002",
                                            "spread": "0.028"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Medial Temporal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.015",
                                            "spread": "0.034"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.010",
                                            "spread": "0.034"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Lateral Temporal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.020",
                                            "spread": "0.029"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.016",
                                            "spread": "0.024"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Post Cingulate - Precuneus",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.017",
                                            "spread": "0.023"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.016",
                                            "spread": "0.018"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Inferior Parietal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.025",
                                            "spread": "0.029"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.018",
                                            "spread": "0.022"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in ADAS-Cog 11 (Alzheimer's Disease Assessment Scale - Cognitive 11) Score",
                    "description": "The ADAS-Cog 11 (Alzheimer's Disease Assessment Scale - Cognitive 11) is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment. Scores from the original portion of the test range from 0 (best) to 70 (worse). We used total ADAS-Cog 11 scores, which is a sum of individual subscales. We calculated the change by subtracting the ADAS Cog score at week 24 from baseline score. A positive change indicates cognitive worsening.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Mean change in scores from baseline to week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nPlacebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Rasagiline",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nRasagiline"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "25"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.76",
                                            "spread": "4.3"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.81",
                                            "spread": "4.43"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in MMSE (Mini Mental Status Examination) Score",
                    "description": "Measure Description: The MMSE (Mini Mental Status Examination) is a brief, frequently used screening instrument for AD drug studies. The MMSE evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons. A lower score indicates more cognitive impairment. The highest score is 30, range is between 0 (severe impairment) and 30 (cognitively normal). We calculated the change in scores by subtracting week 24 score from baseline. A negative score indicates clinical worsening.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Mean change in scores from baseline to week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nPlacebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Rasagiline",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nRasagiline"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "25"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.14",
                                            "spread": "2.27"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.65",
                                            "spread": "2.48"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) Score",
                    "description": "Measure Description: The ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) is an activities-of-daily-living inventory developed by the ADCS to assess functional performance in participants with AD. Using a structured interview format, study partners are queried as to whether participants attempted each item in the inventory during the past 4 weeks and their level of performance. The ADCS-ADL provides a total score from 0-78, with a lower score indicating greater severity. We calculated change by subtracting scores on week 24 test from the baseline score. A negative score indicates worsening ability to complete ADLs.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Mean change in scores from baseline to week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nPlacebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Rasagiline",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nRasagiline"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "25"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-3.23",
                                            "spread": "6.71"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-3.75",
                                            "spread": "7.27"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in NPI (Neuropsychiatric Inventory) Score",
                    "description": "Measure Description: The behavioral outcome measure for this trial is the NPI (Neuropsychiatric Inventory). The NPI evaluates both the frequency and severity of 10 neuropsychiatric disturbances. Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1=mild, 2=moderate, 3=severe). The overall score is calculated by summing the severity and frequency of the subscale measures. The range of scores is 0-40. A score of 0 indicates no behavioral impairment and a score of 40 indicates severe behavioral impairment. We calculated change by subtracting Week 24 scores from baseline scores. A positive change indicates behavioral worsening.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Mean change in scores from baseline to week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nPlacebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Rasagiline",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nRasagiline"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "25"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2",
                                            "spread": "7.18"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.2",
                                            "spread": "6.79"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in Digit Span",
                    "description": "Measure Description: The Digit Span consists of repetition of increasing long strings of digits presented at 1 per second as read by the examiner and repeated by the subject.The score is the maximum number of digits the patient can repeat until they fail twice in a row. The reverse digit span is identical to the forward digit span except that the patient repeats the presented digits in reverse order. The score is the maximum number of digits the patient can repeat in reverse order until they fail twice in a row. Each correct response is worth one point with a maximum total score of 28. A higher score is better. We calculated change by subtracting week 24 score from baseline score. A negative score indicates worse performance over the course of study.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Mean change in scores from baseline to week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nPlacebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Rasagiline",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nRasagiline"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "25"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.18",
                                            "spread": "1.92"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.29",
                                            "spread": "3.08"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in COWAT (Controlled Oral Word Association Test) Score",
                    "description": "Measure Description: Study participants are instructed, \"I want to see how many words you can say beginning with a certain letter in one minute.\" The study participant's responses are recorded on the worksheet. Study participants are then given an additional one minute for each of two different letters using similar instructions. The score is the total number of acceptable words for the three trials combined. A higher score represents better performance.\n\nResponses are then judged for their acceptability (example for the use of proper nouns, numbers, repetitions and stem word with a different ending). The score is the total number of acceptable words for the three trials combined. A higher score represents better performance. We calculated change by subtracting week 24 scores from baseline scores. A negative score indicates worse performance.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Mean change in scores from baseline to week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nPlacebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Rasagiline",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nRasagiline"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "25"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.09",
                                            "spread": "6.31"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.62",
                                            "spread": "5.55"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in QoL-AD (Quality of Life - Alzheimer's Disease) Score",
                    "description": "Measure Description: The QoL-AD (Quality of Life - Alzheimer's Disease) is a commonly used 13 item QoL scale that assesses items specific to QoL in patients with cognitive impairment. It is administered to the research partner with answers for the patient. Points are assigned to each item as follows: poor = 1, fair = 2, good = 3, excellent = 4.The total score is the sum of all 13 items. The range of score is from 0-52. We calculated the change by subtracting the scores on week 24 score from baseline. A negative value indicates worsening quality of life.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "This assessment will be performed at the Baseline and Week 24 visits.",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nPlacebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Rasagiline",
                            "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nRasagiline"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "25"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.95",
                                            "spread": "3.28"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.11",
                                            "spread": "3.77"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "Adverse event data were collected following signing of consent to completion of study week 28 (from May 2016 to August 2018). At each point of contact the research coordinator and PI collected data regarding any new symptoms or laboratory changes.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Placebo",
                    "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nPlacebo",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 25,
                    "seriousNumAffected": 4,
                    "seriousNumAtRisk": 25,
                    "otherNumAffected": 15,
                    "otherNumAtRisk": 25
                },
                {
                    "id": "EG001",
                    "title": "Rasagiline",
                    "description": "Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.\n\nSubjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).\n\nRasagiline",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 25,
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 25,
                    "otherNumAffected": 16,
                    "otherNumAtRisk": 25
                }
            ],
            "seriousEvents": [
                {
                    "term": "confusion",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "delusions",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "atrial fibrillation",
                    "organSystem": "Cardiac disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "stroke",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 25
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Abnormal UA",
                    "organSystem": "Renal and urinary disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "Agitation",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "Confusion",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "Delusions",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "Elevated blood pressure",
                    "organSystem": "Vascular disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "Elevated Thyroid Stimulating Hormone",
                    "organSystem": "Endocrine disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "Insomnia",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 25
                        }
                    ]
                },
                {
                    "term": "Rash/skin lesion",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 25
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 25
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Dr. Aaron Ritter",
                "organization": "Cleveland Clinic Lou Ruvo Center for Brain Health",
                "email": "rittera@ccf.org",
                "phone": "702-483-6049"
            }
        }
    },
    "target_category": "Cognitive enhancer",
    "drug": [
        "Rasagiline (selective MAO-B inhibitor; small molecule, e.g., Azilect)"
    ],
    "placebo": [
        "Placebo"
    ],
    "explanation_target": [
        "Reason: Rasagiline is a selective, irreversible monoamine oxidase\u2011B (MAO\u2011B) inhibitor \u2014 a small\u2011molecule drug (not a biologic) with dopaminergic/neuroprotective effects. \ue200cite\ue202turn0search4\ue202turn0search5\ue201",
        "Act: The described trial is a Phase II, randomized, double\u2011blind, placebo\u2011controlled, 24\u2011week, three\u2011site proof\u2011of\u2011concept study that tested rasagiline vs placebo with the primary outcome change in regional brain glucose metabolism measured by FDG\u2011PET (dose titrated 0.5 mg \u2192 1 mg daily; N=50). This matches NCT02359552 and the published trial report. \ue200cite\ue202turn0search1\ue202turn0search0\ue201",
        "Act (mechanistic/intent): The trial measured FDG\u2011PET (neuronal/metabolic activity) as the primary outcome and reported favorable metabolic changes in frontal/striatal regions and some clinical signals (quality of life, directional cognitive/neuropsychiatric trends). The intervention therefore aims to alter neuronal metabolism/function (symptomatic and possibly neuroprotective), rather than directly targeting core AD pathology such as amyloid or tau (though tau PET was also measured secondarily). \ue200cite\ue202turn0search0\ue202turn0search7\ue201",
        "Reflect / Classification: By the provided category definitions, rasagiline is a small molecule but does not specifically target canonical AD pathology (amyloid or tau). Its mechanism (MAO\u2011B inhibition \u2192 modulate monoamines/neuroprotection; improve neuronal metabolism/function) fits best under 'Cognitive enhancer' (improve cognitive/neuronal function) rather than 'disease\u2011targeted biologic' or a small molecule that directly targets AD pathology. The trial\u2019s FDG\u2011PET endpoint and published results support this interpretation. \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Web search results (sources used): 1) PubMed article reporting the Phase II rasagiline FDG\u2011PET trial and outcomes (effects on FDG\u2011PET, some clinical signals). \ue200cite\ue202turn0search0\ue201 2) ClinicalTrials.gov / trial registry entry for NCT02359552 with study design, dosing, and primary outcome details. \ue200cite\ue202turn0search1\ue201 3) Pharmacology/review describing rasagiline as a selective irreversible MAO\u2011B inhibitor (small molecule; Azilect). \ue200cite\ue202turn0search4\ue202turn0search5\ue201 4) Additional imaging study (SPECT) suggesting rasagiline can affect regional brain perfusion in AD (supporting neurofunctional effects). \ue200cite\ue202turn0search7\ue201"
    ],
    "agent_type": "M) Synaptic Plasticity/Neuroprotection",
    "explanation_agent": [
        "Reason: Rasagiline is a selective, irreversible MAO\u2011B inhibitor (small molecule) that modulates monoamine neurotransmitter metabolism and has reported dopaminergic and neuroprotective effects. The trial\u2019s intent (improve neuronal metabolism/function measured by FDG\u2011PET and produce symptomatic/neuroprotective signals) targets neuronal/synaptic function rather than canonical AD proteinopathies (amyloid or tau).",
        "Act: Extracted details \u2014 drug: Rasagiline (selective MAO\u2011B inhibitor; Azilect); mechanism: inhibition of monoamine oxidase B \u2192 increased monoamine availability / modulation of neurotransmission and reported neuroprotective effects; trial focus: 24\u2011week randomized, double\u2011blind, placebo\u2011controlled proof\u2011of\u2011concept measuring regional brain glucose metabolism (FDG\u2011PET) and clinical signals. Based on CADRO definitions, this intervention is best categorized under M) Synaptic Plasticity/Neuroprotection because it aims to improve neuronal/synaptic function and provide neuroprotection rather than directly modifying amyloid, tau, APOE/lipid pathways, or vascular/metabolic primary targets. (Not assigned to D) Neurotransmitter Receptors because rasagiline targets an enzyme (MAO\u2011B) that alters neurotransmitter metabolism rather than a receptor; additionally, the neuroprotective/synaptic intent aligns better with M.)",
        "Reflect: The classification aligns with the description and CADRO categories: rasagiline does not target amyloid (A) or tau (B), nor is it primarily a metabolic/vascular intervention (J/K) though FDG\u2011PET was used as outcome. An alternative plausible category could be D) Neurotransmitter Receptors if limited to \u2018neurotransmitter system modulation\u2019 broadly, but MAO\u2011B inhibition and the trial\u2019s neuroprotective/metabolic aims make M) Synaptic Plasticity/Neuroprotection the more specific fit. If new mechanistic evidence showed direct modulation of synaptic plasticity pathways distinct from general neuroprotection, reassessment would be warranted.",
        "Web search results (provided by user): 1) PubMed article reporting the Phase II rasagiline FDG\u2011PET trial and outcomes (effects on FDG\u2011PET, some clinical signals). 2) ClinicalTrials.gov / trial registry entry for NCT02359552 with study design, dosing, and primary outcome details. 3) Pharmacology/review describing rasagiline as a selective irreversible MAO\u2011B inhibitor (small molecule; Azilect). 4) Additional imaging study (SPECT) suggesting rasagiline can affect regional brain perfusion in AD (supporting neurofunctional effects)."
    ]
}